FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806853868> ?p ?o ?g. }

• W2806853868 abstract "The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer's disease.A single-centre, double-blind, placebo-controlled, cross-over clinical trial was performed to assess the efficacy of donepezil in patients with PCA. Each patient received either donepezil (5 mg once daily in the first 6 weeks and 10 mg once daily in the second 6 weeks) or placebo for 12 weeks. After a 2-week washout period, each patient received the other treatment arm during the following 12 weeks followed by another 2-week washout period. The primary outcome was the Mini-Mental State Examination (MMSE) at 12 weeks. Secondary outcome measures were five neuropsychological tests reflecting parieto-occipital function. Intention-to-treat analysis was used. For each outcome measure, carry-over effects were first assessed. If present, then analysis was restricted to the first 12-week period. Otherwise, the standard approach to the analysis of a 2 × 2 cross-over trial was used.Eighteen patients (13 females) were recruited (mean age 61.6 years). There was a protocol violation in one patient, who subsequently withdrew from the study due to gastrointestinal side effects. There was statistically significant (p < 0.05) evidence of a carry-over effect on MMSE. Therefore, the analysis of treatment effect on MMSE was restricted to the first 12-week period. Treatment effect at 6 weeks was statistically significant (difference = 2.5 in favour of donepezil, 95% CI 0.1 to 5.0, p < 0.05). Treatment effect at 12 weeks was close, but not statistically significant (difference = 2.0 in favour of donepezil, 95% CI -0.1 to 4.5, p > 0.05). There were no statistically significant treatment effects on any of the five neuropsychological tests, except for digit span at 12 weeks (higher by 0.5 digits in favour of placebo, 95% CI 0.1 to 0.9). Gastrointestinal side effects occurred most frequently, affecting 13/18 subjects (72%), and were the cause of study discontinuation in one subject. Nightmares and vivid dreams occurred in 8/18 subjects (44%), and were statistically more frequent during treatment with donepezil.In this small study, there was no statistically significant treatment effect of donepezil on the primary outcome measure (MMSE score at 12 weeks) in PCA patients, who appear to be particularly susceptible to the development of nightmares and vivid dreams when treated.Trial registration: Current Controlled Trials ISRCTN22636071 . Retrospectively registered 19 May 2010." @default.
• W2806853868 created "2018-06-13" @default.
• W2806853868 creator A5023115414 @default.
• W2806853868 creator A5032315629 @default.
• W2806853868 creator A5032450718 @default.
• W2806853868 creator A5033864057 @default.
• W2806853868 creator A5041200246 @default.
• W2806853868 creator A5044136330 @default.
• W2806853868 creator A5044400361 @default.
• W2806853868 creator A5051266217 @default.
• W2806853868 creator A5062446206 @default.
• W2806853868 creator A5071396875 @default.
• W2806853868 creator A5087343628 @default.
• W2806853868 date "2018-05-01" @default.
• W2806853868 modified "2023-09-25" @default.
• W2806853868 title "A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study" @default.
• W2806853868 cites W117033904 @default.
• W2806853868 cites W1562896067 @default.
• W2806853868 cites W1566945227 @default.
• W2806853868 cites W1847168837 @default.
• W2806853868 cites W1977315588 @default.
• W2806853868 cites W1979011734 @default.
• W2806853868 cites W2006370463 @default.
• W2806853868 cites W2008854521 @default.
• W2806853868 cites W2010232680 @default.
• W2806853868 cites W2013173310 @default.
• W2806853868 cites W2033774309 @default.
• W2806853868 cites W2055727638 @default.
• W2806853868 cites W2058161128 @default.
• W2806853868 cites W2074669441 @default.
• W2806853868 cites W2078718001 @default.
• W2806853868 cites W2081285591 @default.
• W2806853868 cites W2085100897 @default.
• W2806853868 cites W2107052006 @default.
• W2806853868 cites W2138524067 @default.
• W2806853868 cites W2146008734 @default.
• W2806853868 cites W2148080316 @default.
• W2806853868 cites W2167311298 @default.
• W2806853868 cites W2338678376 @default.
• W2806853868 cites W4243834324 @default.
• W2806853868 cites W4246122903 @default.
• W2806853868 cites W4367475339 @default.
• W2806853868 doi "https://doi.org/10.1186/s13195-018-0363-1" @default.
• W2806853868 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5930935" @default.
• W2806853868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29716655" @default.
• W2806853868 hasPublicationYear "2018" @default.
• W2806853868 type Work @default.
• W2806853868 sameAs 2806853868 @default.
• W2806853868 citedByCount "22" @default.
• W2806853868 countsByYear W28068538682019 @default.
• W2806853868 countsByYear W28068538682020 @default.
• W2806853868 countsByYear W28068538682021 @default.
• W2806853868 countsByYear W28068538682022 @default.
• W2806853868 countsByYear W28068538682023 @default.
• W2806853868 crossrefType "journal-article" @default.
• W2806853868 hasAuthorship W2806853868A5023115414 @default.
• W2806853868 hasAuthorship W2806853868A5032315629 @default.
• W2806853868 hasAuthorship W2806853868A5032450718 @default.
• W2806853868 hasAuthorship W2806853868A5033864057 @default.
• W2806853868 hasAuthorship W2806853868A5041200246 @default.
• W2806853868 hasAuthorship W2806853868A5044136330 @default.
• W2806853868 hasAuthorship W2806853868A5044400361 @default.
• W2806853868 hasAuthorship W2806853868A5051266217 @default.
• W2806853868 hasAuthorship W2806853868A5062446206 @default.
• W2806853868 hasAuthorship W2806853868A5071396875 @default.
• W2806853868 hasAuthorship W2806853868A5087343628 @default.
• W2806853868 hasBestOaLocation W28068538681 @default.
• W2806853868 hasConcept C118552586 @default.
• W2806853868 hasConcept C126322002 @default.
• W2806853868 hasConcept C141071460 @default.
• W2806853868 hasConcept C14216870 @default.
• W2806853868 hasConcept C142724271 @default.
• W2806853868 hasConcept C169900460 @default.
• W2806853868 hasConcept C204787440 @default.
• W2806853868 hasConcept C27081682 @default.
• W2806853868 hasConcept C2779134260 @default.
• W2806853868 hasConcept C2779483572 @default.
• W2806853868 hasConcept C2780904820 @default.
• W2806853868 hasConcept C2781172350 @default.
• W2806853868 hasConcept C42219234 @default.
• W2806853868 hasConcept C535046627 @default.
• W2806853868 hasConcept C71924100 @default.
• W2806853868 hasConceptScore W2806853868C118552586 @default.
• W2806853868 hasConceptScore W2806853868C126322002 @default.
• W2806853868 hasConceptScore W2806853868C141071460 @default.
• W2806853868 hasConceptScore W2806853868C14216870 @default.
• W2806853868 hasConceptScore W2806853868C142724271 @default.
• W2806853868 hasConceptScore W2806853868C169900460 @default.
• W2806853868 hasConceptScore W2806853868C204787440 @default.
• W2806853868 hasConceptScore W2806853868C27081682 @default.
• W2806853868 hasConceptScore W2806853868C2779134260 @default.
• W2806853868 hasConceptScore W2806853868C2779483572 @default.
• W2806853868 hasConceptScore W2806853868C2780904820 @default.
• W2806853868 hasConceptScore W2806853868C2781172350 @default.
• W2806853868 hasConceptScore W2806853868C42219234 @default.
• W2806853868 hasConceptScore W2806853868C535046627 @default.
• W2806853868 hasConceptScore W2806853868C71924100 @default.
• W2806853868 hasIssue "1" @default.
• W2806853868 hasLocation W28068538681 @default.
• W2806853868 hasLocation W28068538682 @default.

• next